Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
1,NCT03799718,Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS,,Completed,No Results Available,"Multiple Sclerosis, Chronic Progressive",Biological: NurOwn (MSC-NTF cells),Incidence of treatment-emergent adverse events|Timed 25-foot walking speed or 9-Hole Peg Test - change from baseline.|Number of participants with changes in neurotrophic factors (such as Vascular endothelial growth factor and Hepatocyte growth factor) in the cerebrospinal fluid (CSF) following NurOwn® transplantation,Brainstorm-Cell Therapeutics,All,"18 Years to 65 Years   (Adult, Older Adult)",Phase 2,20,Industry,Interventional,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BCT-101-US,13-Mar-19,11-Mar-21,30-Mar-21,10-Jan-19,,1-Sep-21,"University of Southern California, Los Angeles, California, United States|Stanford University School of Medicine, Redwood City, California, United States|The Mount Sinai Hospital, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT03799718
2,NCT03280056,Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients,,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: NurOwn® (MSC-NTF cells)|Other: Placebo|Other: Bone Marrow aspiration,To evaluate the efficacy and safety of NurOwn® (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers,Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM),All,18 Years to 60 Years   (Adult),Phase 3,263,Industry|Other,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BCT-002-US,28-Aug-17,30-Oct-20,30-Oct-20,12-Sep-17,,6-Oct-21,"University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT03280056
3,NCT02017912,"Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS",NurOwn,Completed,No Results Available,Amyotrophic Lateral Sclerosis (ALS),Biological: Autologous MSC-NTF cells|Biological: Placebo,Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation,Brainstorm-Cell Therapeutics,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,48,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",BCT-001-US,May-14,Mar-16,Jul-16,23-Dec-13,,18-Jul-18,"Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02017912
